Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Financings Of The Fortnight: More Celtics Than At Boston Garden

This article was originally published in The Pink Sheet Daily

Executive Summary

Various Celtic funds were involved in quite a few financing deals over the past two weeks.

You may also be interested in...

Renewing Old Ties, Celtic Therapeutics Leads $10 Million Series B For Kolltan

Financing includes $1.5 million development option that converts to another Series B if there's no agreement on a co-development program.

Nothing Anemic About Ferahame: The Med Helps Amag Exceeds Street Expectations

With a broad label already in place, Amag plans to increase market for chronic kidney disease drug through label and geographic expansion.

Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind

Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts